94581
Hirudin recombinant from yeast
lyophilized powder, white, >1500 U/vial
Sign Into View Organizational & Contract Pricing
Select a Size
1 EA
$1,400.00
$1,400.00
Available to ship onMay 02, 2025Details
Notify Me
Get notified when this item is ready to ship via email.
All Photos(1)
Select a Size
Change View
1 EA
$1,400.00
About This Item
$1,400.00
Available to ship onMay 02, 2025Details
Notify Me
Get notified when this item is ready to ship via email.
Recommended Products
biological source
synthetic
yeast (Pichia pastoris)
Quality Level
form
lyophilized powder
specific activity
>1500 U/vial
mol wt
Mr ~6963.5
color
white
solubility
0.1 M Tris, 0.2 M NaCl, pH 8.4: 1 vial/mL, clear, colorless
storage temp.
−20°C
application
Biochem/physiol Actions
Recombinant hirudin appears to be antigenic. Independent studies have found that 50-70% of patients treated for several days with recombinant hirudin develop at least one hirudin antibody isotype. The antibodies reduce the anticoagulant effect of hirudin, but prolong its plasma half-life by reducing renal filtration.[3]
The anticoagulant, hirudin, is the most potent natural inhibitor of both soluble and clot-bound thrombin. It binds thrombin with high affinity, covering more than 20% of its surface area and occluding both the active site and exosite I (fibrinogen and PAR recognition site). Hirudin blocks thrombus growth and platelet activation. It is not metabolized in the bloodstream of humans and is eliminated unchanged via kidney filtration.
Unit Definition
1 U corresponds to 1 ATU (antithrombin unit; 1 ATU is defined as the amount of inhibitor that neutralizes 1 NIH unit of thrombin).
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
A few immobilized thrombins are sufficient for platelet spreading
Okamura Y, et al.
Biophysical Journal, 100(8), 1855-1863 (2011)
Multiple routes of complement activation by Mycobacterium bovis BCG
Carroll MV, et al.
Molecular Immunology, 46(16), 3367-3378 (2009)
Volker Liebe et al.
Seminars in thrombosis and hemostasis, 28(5), 483-490 (2002-11-07)
This article provides an overview of the clinically relevant characteristics of antibodies directed toward recombinant (r) hirudin, with emphasis on the different ways in which these antibodies may influence pharmacokinetics and pharmacodynamics of r-hirudin. A high incidence of anti-hirudin antibody
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
